Loading…
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $10M | $-108M | $-109M | $-94M | -44.1% | 17.3% | 22.1% |
| 2024 | $8M | $-88M | $-89M | $-82M | -124.8% | -46.1% | -20.0% |
| 2023 | $15M | $-105M | $-112M | $-80M | -148.9% | 517.5% | -32.8% |
| 2022 | $3M | $-161M | $-166M | $-113M | -17493.6% | - | - |
| 2021 |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 2.50 | 15.45 | 8.33 | 9.77 |
| Operating Revenue | - | 2.50 | 15.45 | 8.33 | 9.77 |
| Operating Expense | - | 128.53 | 86.82 | 94.95 | 120.27 |
| Research And Development | - | 91.17 | 56.78 | 66 | 86.40 |
| Selling General And Administration | - | 37.36 | 30.05 | 28.95 | 33.87 |
| Total Expenses | - | 128.53 | 86.82 | 94.95 | 120.27 |
| Operating Income | - | -126.03 | -71.37 | -86.62 | -110.50 |
| Total Operating Income As Reported | - | -162.45 | -72.44 | -91.46 | -110.50 |
| EBITDA | - | -161.04 | -105.20 | -87.95 | -107.79 |
| Normalized EBITDA | - | -124.62 | -68.02 | -83.13 | -106.59 |
| EBIT | - | -162.22 | -106.57 | -89.20 | -108.93 |
| Interest Income | - | 0.25 | 3.57 | 6.94 | 9.22 |
| Interest Expense | - | 3.80 | 5 | 0.10 | 0.06 |
| Net Interest Income | - | -3.55 | -1.43 | 6.84 | 9.16 |
| Other Non Operating Income Expenses | - | -0.02 | -1.58 | -4.69 | -6.46 |
| Other Income Expense | - | -36.44 | -38.77 | -9.52 | -7.66 |
| Interest Income Non Operating | - | 0.25 | 3.57 | 6.94 | 9.22 |
| Interest Expense Non Operating | - | 3.80 | 5 | 0.10 | 0.06 |
| Net Non Operating Interest Income Expense | - | -3.55 | -1.43 | 6.84 | 9.16 |
| Pretax Income | - | -166.01 | -111.57 | -89.30 | -109 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -166.01 | -111.57 | -89.30 | -109 |
| Net Income From Continuing And Discontinued Operation | - | -166.01 | -111.57 | -89.30 | -109 |
| Net Income From Continuing Operation Net Minority Interest | - | -166.01 | -111.57 | -89.30 | -109 |
| Net Income | - | -166.01 | -111.57 | -89.30 | -109 |
| Net Income Common Stockholders | - | -166.01 | -111.57 | -89.30 | -109 |
| Net Income Including Noncontrolling Interests | - | -166.01 | -111.57 | -89.30 | -109 |
| Normalized Income | - | -129.59 | -74.39 | -84.48 | -107.80 |
| Diluted NI Availto Com Stockholders | - | -166.01 | -111.57 | -89.30 | -109 |
| Basic Average Shares | 37.65 | 43.95 | 116.12 | 250.13 | - |
| Diluted Average Shares | 37.65 | 43.95 | 116.12 | 250.13 | - |
| Reconciled Depreciation | - | 1.17 | 1.37 | 1.25 | 1.14 |
| Total Unusual Items | - | -36.42 | -37.18 | -4.82 | -1.20 |
| Total Unusual Items Excluding Goodwill | - | -36.42 | -37.18 | -4.82 | -1.20 |
| Special Income Charges | - | -36.42 | -2.46 | -4.84 | 0 |
| Other Special Charges | - | - | 1.40 | - | - |
| Impairment Of Capital Assets | - | 36.42 | 1.06 | 4.84 | 0 |
| Gain On Sale Of Security | - | - | -34.72 | 0.02 | -1.20 |
| General And Administrative Expense | - | 37.36 | 30.05 | 28.95 | 33.87 |
| Other Gand A | - | 37.36 | 30.05 | 28.95 | 33.87 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Taysha Gene Therapies, Inc.this co. | TSHA | $1.7B | -15.53 | 6.85 | -44.1% | -13.39 |
| UFP Technologies, Inc. | UFPT | $1.7B | 25.43 | 4.10 | 16.1% | 16.79 |
| Biohaven Ltd. | BHVN | $1.7B | -2.32 | 32.96 | -1418.8% | -2.41 |
| Agios Pharmaceuticals, Inc. | AGIO | $1.7B | -4.15 | 1.44 | -34.6% | -3.56 |
| Sionna Therapeutics, Inc. | SION | $1.7B |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| -22.66 |
| 5.56 |
| -24.5% |
| -18.75 |
| Novavax, Inc. | NVAX | $1.7B | 3.81 | -13.12 | -344.7% | 3.42 |
| Addus HomeCare Corporation | ADUS | $1.7B | 17.46 | 1.54 | 8.8% | 11.20 |
| GeneDx Holdings Corp. | WGS | $1.7B | -79.47 | 5.42 | -6.8% | 138.20 |
| Palvella Therapeutics, Inc. | PVLA | $1.6B | -39.48 | 58.85 | -149.1% | -44.28 |
| Peer Median | - | -3.24 | 4.76 | -29.6% | 0.51 | |